Zealand Pharma A/S

Zealand Pharma A/S

ZEAL

ZEALZealand Pharma A/S US flag

NASDAQ Global Select

17.59

USD

- -

- -

CIK

0001674988

ISIN

US98920Y3045

CUSIP

98920Y304

Return %

Stock

S&P500

1Y

6.22

26.53

3Y

-54.31

76.60

5Y

16.26

80.11

Use logarithmic scale

No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Company Description

CEO: Emmanuel Dulac PharmD, MBA
Full Time Employees: 237
Sector: Healthcare
Industry: Biotechnology
Address: Sydmarken 11 Copenhagen Denmark 2860
IPO Date: Aug 9, 2017
CIK: 0001674988
Website: zealandpharma.com
Similar Companies: Denali Therapeutics Inc. (DNLI)
AIkido Pharma Inc. (AIKI)
TC Biopharm (Holdings) Plc (TCBPW)
Genscript Biotech Corporation (1548.HK)
Awakn Life Sciences Corp. (AWKNF)
Starpharma Holdings Limited (SPL.AX)
Business: Zealand Pharma A/S, a biotechnology company focused on the discovery, design, development, and commercialization of innovative peptide-based medicines addressing unmet medical needs, operates primarily in the areas of obesity, rare diseases, and chronic inflammation. Founded in 1998 and headquartered in Søborg, Denmark, with additional operations in the United States, the company offers a pipeline of investigational candidates including petrelintide, a long-acting amylin analog for weight management; dapiglutide, a long-acting GLP-1/GLP-2 receptor dual agonist targeting obesity and low-grade inflammation; survodutide, a long-acting glucagon/GLP-1 receptor dual agonist licensed to Boehringer Ingelheim for obesity and metabolic dysfunction-associated steatohepatitis; ZP6590, a GIP receptor agonist for obesity; dasiglucagon for continuous infusion in congenital hyperinsulinism and other formulations such as Zegalogue for severe hypoglycemia; glepaglutide, a long-acting GLP-2 analog for short bowel syndrome; ZP9830, a Kv1.3 ion channel blocker for T-cell-driven autoimmune diseases; and ZP10068, a complement C3 inhibitor for complement-mediated diseases. Zealand Pharma targets patients with metabolic, gastrointestinal, and inflammatory conditions globally through research, clinical development, and strategic partnerships. In recent developments, the company entered an exclusive collaboration and licensing agreement with Roche in March 2025 to co-develop and co-commercialize petrelintide as a monotherapy and in fixed-dose combination with Roche's CT-388 for obesity, providing upfront payments of USD 1.65 billion and potential total consideration up to USD 5.3 billion; closed this agreement in May 2025 with Phase 2b ZUPREME trials advancing; submitted a Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome; reported positive topline results from a 28-week Phase 1b trial of dapiglutide; completed an upsized equity offering raising approximately DKK 835 million in June 2024 to fund obesity programs; and appointed Steven Johnson as Chief Development Officer to strengthen leadership in obesity innovation.

Company News